1.91
0.06 (3.24%)
| Penutupan Terdahulu | 1.85 |
| Buka | 1.86 |
| Jumlah Dagangan | 1,930,024 |
| Purata Dagangan (3B) | 1,290,910 |
| Modal Pasaran | 162,339,040 |
| Harga / Jualan (P/S) | 77.32 |
| Harga / Buku (P/B) | 11.13 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 12 Nov 2025 |
| EPS Cair (TTM) | -0.770 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 416.80% |
| Nisbah Semasa (MRQ) | 4.66 |
| Aliran Tunai Operasi (OCF TTM) | -33.87 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -19.45 M |
| Pulangan Atas Aset (ROA TTM) | -41.29% |
| Pulangan Atas Ekuiti (ROE TTM) | -307.27% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Milestone Pharmaceuticals Inc. | Menurun | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | -0.5 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 1.0 |
| Osilator Teknikal | 4.0 |
| Purata | 0.63 |
|
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular medicines. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to treat episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR). |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 4.71% |
| % Dimiliki oleh Institusi | 22.25% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Cascades Capital Asset Management, Llc | 30 Jun 2025 | 67,135 |
| Julat 52 Minggu | ||
| Median | 4.00 (109.42%) | |
| Jumlah | 1 Beli | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Wells Fargo | 11 Sep 2025 | 4.00 (109.42%) | Beli | 1.91 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |